Holen Sie sich die Stockscreener-App
6.20
0.98%
0.06
Handel nachbörslich:
6.32
0.12
+1.94%
Schlusskurs vom Vortag:
$6.14
Offen:
$6.12
24-Stunden-Volumen:
309.46K
Relative Volume:
0.68
Marktkapitalisierung:
$72.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.21M
KGV:
-1.4251
EPS:
-4.3505
Netto-Cashflow:
$-17.41M
1W Leistung:
+6.16%
1M Leistung:
-3.58%
6M Leistung:
+51.59%
1J Leistung:
+64.02%
1-Tages-Spanne:
$6.09
$6.72
1-Wochen-Bereich:
$5.63
$6.76
52-Wochen-Spanne:
$3.20
$11.89
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
6.20 | 71.40M | 0 | -22.21M | -17.41M | -4.3505 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
Energy Moves: Is Cingulate Inc likely to announce a buyback2026 Price Action Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
CING SEC FilingsCingulate Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cingulate Adds Independent Director Jiang to Board Committees - The Globe and Mail
Cingulate appoints Zhanpeng Jiang to board of directors and key committees - au.investing.com
Cingulate Appoints Zhanpeng Jiang to Board of Directors - National Today
Cingulate appoints Zhanpeng Jiang to board of directors and key committees By Investing.com - Investing.com South Africa
Zhanpeng Jiang joins Cingulate (CING) board with option for 15,000 shares - Stock Titan
Revenue Check: Can Cingulate Inc Equity Warrant sustain earnings growth2026 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Revenue Check: Is Cingulate Inc Equity Warrants ROE strong enough2026 Sector Review & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Earnings Miss: Can Cingulate Inc Equity Warrant maintain its current growth rate2026 AllTime Highs & Weekly Setup with High ROI Potential - baoquankhu1.vn
Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst - MSN
Cingulate (CING) registers 3.5M shares for Lincoln Park under $25M equity line - stocktitan.net
Falcon Creek discloses 28.5% Cingulate (CING) ownership stake - Stock Titan
Wall Street Recap: What is the target price for Cingulate Inc Equity Warrant stockMarket Trend Summary & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
FOMO Trade: Is Cingulate Inc currently under institutional pressureMarket Trend Report & Smart Money Movement Tracker - baoquankhu1.vn
Cingulate Announces ATM Equity Program and Share Issuance - The Globe and Mail
[EFFECT] Cingulate Inc. SEC Filing - Stock Titan
Can Cingulate Inc Equity Warrant sustain earnings growthWeekly Trade Review & Trade Opportunity Analysis - baoquankhu1.vn
Cingulate Inc. Enters ATM Sales Agreement with A.G.P./Alliance Global Partners for Common Stock Offering – March 2026 - Minichart
Cingulate Inc has submitted a prospectus supplement to the U.S. Securities and Exchange Commission, planning to conduct a market offering and sell common shares in phases for a total amount of up to 100 million dollars. - Bitget
Cingulate (NASDAQ: CING) adds $100M ATM share sale capacity - Stock Titan
Cingulate Inc. (NASDAQ: CING) launches up to $100M ATM sales program - Stock Titan
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Roth Capital Lowers Price Target for Cingulate (CING) to $14, Ma - GuruFocus
Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00 - marketbeat.com
Cingulate (NASDAQ: CING) files S-3/A amendment adding KPMG consent - Stock Titan
If You Invested $1,000 in Cingulate Inc (CING) - Stock Titan
History Review: Is Cingulate Inc likely to announce a buyback2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - MSN
What's going on with Cingulate stock today? - MSN
Stock Report: How cyclical is Cingulate Inc Equity Warrants revenue stream2026 Valuation Update & Long Hold Capital Preservation Plans - baoquankhu1.vn
CING: Laying the Foundation for 1H:27 Launch - Research Tree
What's Going On With Cingulate Stock Today? - Benzinga
3.5M-share resale registration by Cingulate (NASDAQ: CING) under Lincoln Park deal - Stock Titan
Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
Cingulate (CING) Expected to Announce Earnings on Thursday - MarketBeat
Cingulate Reports 2025 Financial Results, Advances CTx-1301 ADHD Drug with New Patents and NDA Progress - Minichart
Cingulate Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Bitget
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. Advances Precision Timed Release ADHD and Anxiety Treatments with Innovative Drug Delivery Platform – 2025 Annual Report Highlights - Minichart
Cingulate (CING) outlines CTx-1301 FDA review, ADHD market and PTR pipeline - Stock Titan
Cingulate 10-K: $0 Revenue, $(22.45)M Net Loss - TradingView
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - Benzinga
CING: 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised - TradingView
CING: NDA for CTx-1301 accepted, $12M raised, and cash runway extends into late Q4 2026 - TradingView
CING: 2025 net loss widened to $22.4M; cash runway into late 2026, pending CTx-1301 FDA approval - TradingView
Patent wins and $12M PIPE support Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cingulate Inc-Aktie (CING) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Callahan Jennifer L. | SVP and CFO |
Feb 06 '26 |
Buy |
5.04 |
4,864 |
24,515 |
5,059 |
| Schaffer Shane J. | Chief Executive Officer |
Feb 06 '26 |
Buy |
5.04 |
6,809 |
34,317 |
10,175 |
| Brams Matthew | EVP and Chief Medical Officer |
Feb 06 '26 |
Buy |
5.04 |
1,946 |
9,808 |
4,656 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):